Photoacoustic microscopy: a potential new tool for evaluation of angiogenesis inhibitor.

Photoacoustic microscopy: a potential new tool for evaluation of angiogenesis inhibitor.
复制标题

DOI:
10.1364/boe.4.002657
复制
发表时间:
2013-11
影响因子:
3.4
通讯作者:
Sung-Liang Chen;Joseph P. Burnett;Duxin Sun;Xunbin Wei;Zhixing Xie;Xueding Wang
Sung-Liang Chen;Joseph P. Burnett;Duxin Sun;Xunbin Wei;Zhixing Xie;Xueding Wang
中科院分区:
医学2区
文献类型:
--
作者:
Sung-Liang Chen;Joseph P. Burnett;Duxin Sun;Xunbin Wei;Zhixing Xie;Xueding Wang

文献摘要

相似文献

在鸡胚模型上研究了光声显微镜(PAM)评价血管生成抑制剂的可行性。将不同浓度的血管生成抑制剂舒尼替尼应用于鸡胚的绒毛尿囊膜(CAM)。使用激光扫描PAM系统获得胚胎CAM中微血管的成像;而捕获用于比较的同一组CAM的微血管图像的光学显微镜(OM)用作验证PAM结果的金标准。在PAM和OM图像中,微血管密度作为应用舒尼替尼浓度的函数进行了定量。这两种模式的结果有很好的一致性,表明PAM可以提供一个客观评价抗血管生成药物的微血管密度的无偏量化。与仅能进行二维表面成像的传统OM相比,PAM能够对微血管进行三维分析,不仅包括形态学,还包括功能,如犬膀胱模型上的成像结果所部分证明的。新兴的PAM技术显示出在临床和临床前环境中用于全面和客观地评价抗血管生成药物的前景。
The feasibility of photoacoustic microscopy (PAM) for evaluation of angiogenesis inhibitor was investigated on a chick embryo model in vivo. Different concentrations of the angiogenesis inhibitor, Sunitinib, were applied to the chorioallantoic membrane (CAM) of the chick embryos. Imaging of microvasculature in embryo CAMs was acquired using a laser-scanning PAM system; while the optical microscopy (OM) capturing the microvascular images of the same set of CAMs for comparison served as a gold standard for validating the results from PAM. The microvascular density as a function of applied Sunitinib concentration has been quantified in both PAM and OM images. The results from these two modalities have a good agreement, suggesting that PAM could provide an unbiased quantification of microvascular density for objective evaluation of anti-angiogenesis medication. In comparison with conventional OM which enables only two-dimensional enface imaging, PAM is capable of three-dimensional analysis of microvessels, including not only morphology but also functions, as demonstrated in part by the imaging result on a canine bladder model. The emerging PAM technique shows promise to be used in clinical and preclinical settings for comprehensive and objective evaluation of anti-angiogenesis medications.